App-Quantinova.ai

Factors associated with venous thromboembolism among pancreatic cancerpatients.

Ankit Mangla - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

A predictive model for venous thromboembolism in patients with germ-cell tumors receiving chemotherapy.

Enrique Gonzalez-Billalabeitia - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Androgen deprivation therapy use and the risk of venous thromboembolism.

Adi Joseph Klil-Drori - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Androgen Tear

Permanent inferior vena cava filters in patients with active malignancy.

Suneel Deepak Kamath - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.

Gerard Zalcman - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Bevacizumab

Impact of low molecular weight heparin on overall survival in patients with advanced lung cancer: A retrospective study.

Shuchi Gulati - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Heparin

MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).

Paul G. Richardson - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Dexamethasone

Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

Annie Young - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

rivaroxaban

Biochemical profile and clinical characteristics of patients with suspected deep vein thrombosis and pulmonary embolism treated at the Barretos Cancer Hospital.

Lucio Flavio Barbour Fernandes - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study.

Alok A. Khorana - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Tinzaparin

Efficacy and safety of rivaroxaban in Brazilian oncologic patients with thrombosis.

Gustavo Dos Santos Fernandes - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

rivaroxaban

Incidence of catheter-related venous thromboembolism in peripherally inserted central venous catheters vs tunneled chest central venous catheters in patients with hematologic malignancies.

Thomas A. Giever - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Practice patterns for prophylaxis and treatment of cancer related venous thromboembolism (VTE) in Germany: Comparison hematologists/oncologists (HOs) vs. angiologists/phlebologists (APs).

Axel Matzdorff - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Splanchnic vein thrombosis in ambulatory pancreatic cancer patients receiving chemotherapy.

Vanessa Pachn Olmos - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Treatment of venous thromboembolism in ambulatory cancer patients in Germany: A prospective noninterventional study.

Axel Matzdorff - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Long-term venous thromboembolism (VTE) recurrences and bleedings according to cancer site: Data from the RIETE registry.

Isabelle Mahe - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment

Carpenter J - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Capecitabine

A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response

Hirshfield KM - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Bevacizumab

A phase II study of Foretinib for triple negative metastatic breast cancer: NCIC CTG IND 197

Rayson D - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Foretinib

Incidence and risk factors of deep venous thrombosis detected by routine surveillance ultrasonography before surgery in patients with gastric cancer

Y. Tanizawa - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Filters

7277 Abstracts